Clinical usefulness of free and complexed PSA

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 55, Issue S221, 1995, Pages 32-34

  Prestigiacomo, A F ^a   Stamey, T A ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ARTICLE; BLOOD; COMPARATIVE STUDY; HUMAN; MALE; PREDICTION AND FORECASTING; PROSTATE HYPERTROPHY; PROSTATE TUMOR; CANCER DIAGNOSIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER;

COMPARATIVE STUDY; HUMAN; MALE; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 0028963814     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365519509090561     Document Type: Article

References (6)

1. A complex between prostate-specific antigen and α-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer
2. Prostate-specific antigen in human serum occurs predominantly in complex with α-1-antichymotrypsin
3. Significance of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to α-1-antichymotrypsin
4. Morphometric and clinical studies on 68 consecutive radical prostatectomies
5. Making the most out of six systematic sextant biopsies
6. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6 630 men